Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 4/20 | 0.42 |
| ▸ | AGXT | P21549 | 2/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | SOD1 | P00441 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL487468 | 0.91 | IDO1 (0.48) | IDO1AGXTFFAR1ERN1MAOB | |
| SCHEMBL8750461 | 0.84 | TSHR (0.50) | TP53KDM4EALDH1A1IDO1AGXT | |
| SCHEMBL9544860 | 0.83 | FFAR1 (0.41) | IDO1AGXTFFAR1 | |
| SCHEMBL14962810 | 0.83 | IDO1 (0.40) | TP53IDO1AGXTFFAR1ERN1 | |
| SCHEMBL166894 | 0.83 | TP53 (0.61) | TP53ALDH1A1IDO1MGLLCYP1A2 | |
| SCHEMBL19567996 | 0.81 | BCL2 (0.50) | TP53AGXTFFAR1ERN1BCL2 | |
| SCHEMBL10015636 | 0.80 | PTGS2 (0.46) | TP53ALDH1A1CYP1A2CYP2A6 | |
| SCHEMBL10063636 | 0.80 | PTGS2 (0.46) | TP53ALDH1A1CYP1A2CYP2A6 | |
| SCHEMBL13274041 | 0.80 | SOD1 (0.42) | TP53KDM4EALDH1A1IDO1AGXT | |
| SCHEMBL14700071 | 0.80 | IDO1 (0.64) | IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| WO-2021154966-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | KAMARI PHARMA LTD. (IL) | 2021-08-05 | — | — | WO | disclosed |
| US-10544124-B2 | Substituted 2-(het)arylimidazolylcarboxyamides as pesticides | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2020-01-28 | — | — | US | disclosed |
| US-10392377-B2 | Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors | UNIVERSITAT BERN (CH) | 2019-08-27 | — | — | US | disclosed |
| US-10308975-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190047982-A1 | Substituted 2-(het)arylimidazolylcarboxyamides as pesticides | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-02-14 | — | — | US | disclosed |
| US-20180223330-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| EP-2534152-B1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9924073-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates and preparation method thereof | PROMEGA CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA SA (CH) | 2010-01-07 | — | — | US | disclosed |
| US-7531533-B2 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| US-7417053-B2 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
| US-20070254920-A1 | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use | AERIE PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-03-29 | — | — | US | disclosed |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | CHRNA5, GABRA5, GABRB3 | TP53 4865/4885KDM4E 2122/4885ALDH1A1 3515/4885 |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAP4K2, MAPKAPK5 | TP53 243/4885KDM4E 1877/4885ALDH1A1 3152/4885 |
| US-20190047982-A1 | Substituted 2-(het)arylimidazolylcarboxyamides as pesticides | DDT, CYP4X1, CYP4Z1 | TP53 4135/4885KDM4E 231/4885ALDH1A1 3432/4885 |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | REN, PAH, ACE | TP53 3660/4885KDM4E 1290/4885ALDH1A1 412/4885 |
| US-10392377-B2 | Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors | CNR2, CNR1, GPR18 | TP53 4774/4885KDM4E 4056/4885ALDH1A1 609/4885 |
| US-20070254920-A1 | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use | HCAR1, HCAR2, PAICS | TP53 2769/4885KDM4E 3612/4885ALDH1A1 102/4885 |
| US-20180223330-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | TP53 3508/4885KDM4E 3302/4885ALDH1A1 3541/4885 |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | WNT1, CYP11B2, CYP11B1 | TP53 4008/4885KDM4E 1919/4885ALDH1A1 1638/4885 |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TP53 1474/4885KDM4E 190/4885ALDH1A1 2776/4885 |
| US-10308975-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | AADAC, PGLS, GLB1 | TP53 2534/4885KDM4E 4263/4885ALDH1A1 1104/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | TP53 612/4885KDM4E 624/4885ALDH1A1 3736/4885 |
| US-10544124-B2 | Substituted 2-(het)arylimidazolylcarboxyamides as pesticides | DDT, CYP4X1, CYP4Z1 | TP53 4135/4885KDM4E 231/4885ALDH1A1 3432/4885 |
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | TP53 4092/4885KDM4E 3977/4885ALDH1A1 422/4885 |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | RPS6KB1, RPS6KA1, RPS3A | TP53 3540/4885KDM4E 2645/4885ALDH1A1 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.